Researchers have suggested that these limited effects of anti-VEGF/VEGFR drugs may be due to the heterogeneous nature of tumor structures and the susceptibility of tumor blood vessels to anti-angiogenic therapy in different types of cancer [2]. Here, VEGFA is linked to neoplasm.